

# Safety and immunogenicity of the SARS-CoV-2 BNT162b2 vaccine in Chinese adults: a randomized, placebo-controlled, double-blind, phase 3 trial

Nature Medicine

27, 1062-1070

DOI: [10.1038/s41591-021-01330-9](https://doi.org/10.1038/s41591-021-01330-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. <i>Emerging Microbes and Infections</i> , 2021, 10, 1598-1608.	3.0	76
3	Influenza Virus and SARS-CoV-2 Vaccines. <i>Journal of Immunology</i> , 2021, 206, 2509-2520.	0.4	11
4	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. <i>Nature</i> , 2021, 596, 417-422.	13.7	549
9	Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. <i>American Heart Journal Plus</i> , 2021, 8, 100042.	0.3	20
11	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	89
12	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <i>International Immunology</i> , 2021, 33, 529-540.	1.8	28
13	BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. <i>Frontiers in Immunology</i> , 2021, 12, 743422.	2.2	10
14	Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 56-63.	4.6	117
15	Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients. <i>Microbiology Spectrum</i> , 2021, 9, e0059021.	1.2	27
16	A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. <i>International Immunopharmacology</i> , 2021, 100, 108162.	1.7	65
17	Immunogenicity and Safety of the COVID-19 Vaccines Compared With Control in Healthy Adults: A Qualitative and Systematic Review. <i>Value in Health</i> , 2021, , .	0.1	7
18	Associations between Allelic Variants of the Human IgH 3' Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2021, 9, 1207.	2.1	8
19	T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. <i>British Journal of Haematology</i> , 2022, 196, 548-558.	1.2	73
20	What Happens to the Immune System after Vaccination or Recovery from COVID-19?. <i>Life</i> , 2021, 11, 1152.	1.1	5
21	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. <i>Npj Vaccines</i> , 2021, 6, 128.	2.9	102
22	Mechanisms underpinning poor antibody responses to vaccines in ageing. <i>Immunology Letters</i> , 2022, 241, 1-14.	1.1	28
23	Host factors and vaccine efficacy: Implications for COVID-19 vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 1330-1335.	2.5	40
24	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. <i>Vaccines</i> , 2021, 9, 1345.	2.1	22

#	ARTICLE	IF	CITATIONS
25	Multifunctional Dendronized Polypeptides for Controlled Adjuvanticity. <i>Biomacromolecules</i> , 2021, , .	2.6	5
26	Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People. <i>Frontiers in Immunology</i> , 2021, 12, 778679.	2.2	54
27	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. <i>Vaccines</i> , 2021, 9, 1387.	2.1	51
28	Developmental Aspects of SARS-CoV-2, Potential Role of Exosomes and Their Impact on the Human Transcriptome. <i>Journal of Developmental Biology</i> , 2021, 9, 54.	0.9	5
29	Comprehensive Analysis of CD4+ T Cell Response Cross-Reactive to SARS-CoV-2 Antigens at the Single Allele Level of HLA Class II. <i>Frontiers in Immunology</i> , 2021, 12, 774491.	2.2	6
30	Potential Application of Bionanoparticles to Treat Severe Acute Respiratory Syndrome Coronavirus-2 Infection. <i>Frontiers in Nanotechnology</i> , 2022, 3, .	2.4	5
31	Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet Microbe</i> , The, 2022, 3, e193-e202.	3.4	45
33	Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials. <i>JAMA Network Open</i> , 2022, 5, e2143955.	2.8	99
34	Acute myocarditis following COVID-19 mRNA vaccination: a paediatric case. <i>Cardiology in the Young</i> , 2022, 32, 1178-1180.	0.4	7
35	A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines. <i>Journal of Primary Care and Community Health</i> , 2022, 13, 215013192210892.	1.0	21
36	Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review. <i>Vaccines</i> , 2022, 10, 313.	2.1	5
37	COVID-19 mRNA vaccines: Platforms and current developments. <i>Molecular Therapy</i> , 2022, 30, 1850-1868.	3.7	102
38	Enzyme-Linked Immunosorbent Assay: An Adaptable Methodology to Study SARS-CoV-2 Humoral and Cellular Immune Responses. <i>Journal of Clinical Medicine</i> , 2022, 11, 1503.	1.0	4
39	mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2040330.	1.4	5
40	Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old. <i>Frontiers in Immunology</i> , 2022, 13, 812126.	2.2	16
42	Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials. <i>F1000Research</i> , 0, 11, 299.	0.8	0
43	Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm. <i>Journal of Personalized Medicine</i> , 2022, 12, 386.	1.1	5
45	Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study. <i>EBioMedicine</i> , 2022, 78, 103962.	2.7	8

#	ARTICLE	IF	CITATIONS
46	SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: An observational study. <i>International Journal of Infectious Diseases</i> , 2022, 118, 95-103.	1.5	24
47	Capturing adaptive immunity against SARS-CoV-2 in patients with cancer. <i>Nature Cancer</i> , 2021, 2, 1298-1300.	5.7	2
48	The COVID-19 pandemic in children and young people during 2020-2021: A complex discussion on vaccination. <i>Journal of Global Health</i> , 2021, 11, 01011.	1.2	14
49	COVID-19 Vaccination in Children: An Open Question. <i>Current Pediatric Reviews</i> , 2022, 18, 226-236.	0.4	5
50	Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67.	1.9	26
51	Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine. <i>Journal of Medical Virology</i> , 2022, 94, 1566-1580.	2.5	26
52	Targeting strategies for mRNA delivery. <i>Materials Today Advances</i> , 2022, 14, 100240.	2.5	15
53	Advances in COVID-19 mRNA vaccine development. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 94.	7.1	177
54	Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial. <i>Vaccine</i> , 2022, 40, 3380-3388.	1.7	13
55	Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. <i>Reviews in Medical Virology</i> , 2023, 33, e2359.	3.9	17
56	Review of current vaccine development platform to prevent coronavirus disease. <i>National Journal of Maxillofacial Surgery</i> , 2022, 13, 337.	0.1	1
58	Immunogenicity and Safety of BNT162b2 mRNA Vaccine in Chinese Adults: A Randomized Clinical Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
59	COVID-19: VARIANTS, VACCINES, AND ADVERSE REACTIONS. <i>Innovare Journal of Medical Sciences</i> , 0, , 6-13.	0.2	0
60	Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination. <i>Nature Communications</i> , 2022, 13, .	5.8	12
61	Tachycardia following Pfizer-BioNTech COVID-19 vaccine. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2022, , .	0.3	4
62	Side Effects Related to BNT162b2 and CoronaVac Vaccine Requiring Emergency Department Visit. <i>Avicenna Journal of Medicine</i> , 2022, 12, 081-086.	0.3	1
63	Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial. <i>Advances in Therapy</i> , 2022, 39, 3789-3798.	1.3	3
64	Liposome-Based Carbohydrate Vaccine for Simultaneously Eliciting Humoral and Cellular Antitumor Immunity. <i>ACS Macro Letters</i> , 2022, 11, 975-981.	2.3	2

#	ARTICLE	IF	CITATIONS
65	B cellâ€™s intrinsic changes with age do not impact antibodyâ€™secreting cell formation but delay B cell participation in the germinal centre reaction. <i>Aging Cell</i> , 2022, 21, .	3.0	10
66	Herpetic Eye Disease Following the SARS-CoV-2 Vaccinations. <i>Ocular Immunology and Inflammation</i> , 2023, 31, 1151-1162.	1.0	9
67	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. <i>Nature Communications</i> , 2022, 13, .	5.8	27
68	Efficacy and safety of COVIDâ€™19 vaccines: A network metaâ€™analysis. <i>Journal of Evidence-Based Medicine</i> , 2022, 15, 245-262.	0.7	14
69	Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	19
70	The pre-exposure SARS-CoV-2-specific Tâ€™cell repertoire determines the quality of the immune response to vaccination. <i>Immunity</i> , 2022, 55, 1924-1939.e5.	6.6	21
71	SARS-CoV-2 immunity and vaccine strategies in people with HIV. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	12
72	Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
73	Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial. <i>International Journal of Infectious Diseases</i> , 2022, 124, 21-26.	1.5	4
74	Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 29, 100586.	1.3	6
75	SARS CoV-2 IgG Positivity Among the People in Dhaka City: An Observation from the Post Vaccine Period. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
76	Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis. <i>PLoS ONE</i> , 2022, 17, e0273676.	1.1	5
77	Single-cell sequencing of PBMC characterizes the altered transcriptomic landscape of classical monocytes in BNT162b2-induced myocarditis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
78	Geriatric Health Care During the COVID-19 Pandemic: Managing the Health Crisis. <i>Clinical Interventions in Aging</i> , 0, Volume 17, 1365-1378.	1.3	10
79	Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	11
80	Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort. <i>Vaccines</i> , 2022, 10, 1542.	2.1	9
81	COVID-19 Vaccine in Inherited Metabolic Disorders Patients: A Cross-Sectional Study on Rate of Acceptance, Safety Profile and Effect on Disease. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12227.	1.2	1
82	Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2023, 76, 201-209.	2.9	10

#	ARTICLE	IF	CITATIONS
83	Antineutrophil Cytoplasmic Antibody-associated Vasculitis after COVID-19 Vaccination with Pfizer-BioNTech. <i>Internal Medicine</i> , 2022, 61, 2925-2929.	0.3	11
84	BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12–17 years in Scotland. <i>Lancet Regional Health - Europe, The</i> , 2022, 23, 100513.	3.0	8
85	Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine. <i>Cell Host and Microbe</i> , 2022, 30, 1732-1744.e7.	5.1	7
86	Willingness of Older Adults with Chronic Diseases to Receive a Booster Dose of Inactivated Coronavirus Disease 2019 Vaccine: A Cross-Sectional Study in Taizhou, China. <i>Vaccines</i> , 2022, 10, 1665.	2.1	2
87	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
88	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	3
90	COVID-19 Era and the Constantly Reemerging Novel SARS-CoV-2 Variants Calls for Special Attention for the Geriatrics: A Real Challenge. <i>Geriatrics (Switzerland)</i> , 2022, 7, 143.	0.6	3
91	Roles of RNA-binding proteins in neurological disorders, COVID-19, and cancer. <i>Human Cell</i> , 2023, 36, 493-514.	1.2	2
92	Efficacy and safety of COVID-19 vaccines. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	60
93	Tachycardia following Pfizer-BioNTech COVID-19 vaccine. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed )</i> , 2023, 41, 62-63.	0.2	0
94	Antibody responses elicited by mRNA vaccination in firefighters persist six months and correlate inversely with age and directly with BMI. <i>Heliyon</i> , 2023, 9, e12746.	1.4	1
95	Efficacy and Safety of COVID-19 Vaccination in Older Adults: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2023, 11, 33.	2.1	11
96	A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	10